Page 54 - AN-2-1

Advanced Neurology Piribedil for Parkinson’s disease

motor and non-motor symptoms of Parkinson disease. CNS https://doi.org/10.1007/BF00819564
Drugs, 30: 703–717.
41. Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al.,
https://doi.org/10.1007/s40263-016-0360-5 2004, Efficacy and safety of piribedil in early combination
with L-dopa in the treatment of Parkinson’s disease:
30. Mittur A, 2011, Piribedil: Antiparkinsonian properties and
potential clinical utility in dopaminergic disorders. Curr A 6-month open study. J Med Assoc Thai, 87: 1293–1300.
Drug Ther, 6: 17–34. 42. Ziegler M, Castro-Caldas A, Del Signore S, et al., 2003, Efficacy
of piribedil as early combination to levodopa in patients with
31. Lebrun-Frenay C, Borg M, 2002, Choosing the right
dopamine agonist for patients with Parkinson’s disease. Curr stable Parkinson’s disease: A 6-month, randomized, placebo-
Med Res Opin, 18: 209–214. controlled study. Mov Disord, 18: 418–425.
https://doi.org/10.1002/mds.10359
https://doi.org/10.1185/030079902125000741
43. Cheng YB, Qian JJ, Mao CJ, et al., Influence of piribedil on
32. Nyholm D, 2006, Pharmacokinetic optimisation in
the treatment of Parkinson’s disease : An update. Clin non-motor symptoms in early Parkinson’s Disease. Chin J
Pharmacokinet, 45: 109–136. Clin Neurosci, 15: 119–122.
44. Eggert K, Öhlwein C, Kassubek J, et al., 2014, Influence of the
https://doi.org/10.2165/00003088-200645020-00001
nonergot dopamine agonist piribedil on vigilance in patients
33. Stocchi F, 2009, The therapeutic concept of continuous with Parkinson Disease and excessive daytime sleepiness
dopaminergic stimulation (CDS) in the treatment of (PiViCog-PD): An 11-week randomized comparison trial
Parkinson’s disease. Parkinsonism Relat Disord, 15: S68–S71. against pramipexole and ropinirole. Clin Neuropharmacol,
https://doi.org/10.1016/S1353-8020(09)70784-9 37: 116–122.
34. Peihua L, Jianqin W, 2018, Clinical effects of piribedil in https://doi.org10.1097/WNF.0000000000000041
adjuvant treatment of Parkinson’s disease: A meta-analysis. 45. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al.,
Open Med (Wars), 13: 270–277. 1989, Piribedil therapy in Parkinson’s disease. Use of the
https://doi.org/10.1515/med-2018-0041 drug in the retard form. Clin Neuropharmacol, 12: 23–28.
35. Brainin M, Barnes M, Baron JC, et al., 2004, Guidance for 46. Nagaraja D, Jayashree S, 2001, Randomized study of the
the preparation of neurological management guidelines by dopamine receptor agonist piribedil in the treatment of mild
EFNS scientific task forces--revised recommendations 2004. cognitive impairment. Am J Psychiatry, 158: 1517–1519.
Eur J Neurol, 11: 577–581. https://doi.org/10.1176/appi.ajp.158.9.1517
https://doi.org/10.1111/j.1468-1331.2004.00867.x 47. Thobois S, Lhommée E, Klinger H, et al., 2013, Parkinsonian
36. Evidente VG, Esteban RP, Domingo FM, et al., 2003, apathy responds to dopaminergic stimulation of D2/D3
Piribedil as an adjunct to levodopa in advanced Parkinson’s receptors with piribedil. Brain, 136: 1568–1577.
disease: The Asian experience. Parkinsonism Relat Disord, https://doi.org/10.1093/brain/awt067
10: 117–121.
48. Lokk J, Delbari A, 2012, Clinical aspects of palliative care in
https://doi.org/10.1016/s1353-8020(03)00096-8 advanced Parkinson’s disease. BMC Palliat Care, 11: 20.
37. Gong X, Zhang L, Wang J, 2016, The efficacy of levodopa https://doi.org/10.1186/1472-684X-11-20
and benserazide combined piribedil in the treatment of
Parkinson’s disease. Clin Res Pract, 1: 86–87. 49. Thobois S, Ardouin C, Lhommée E, et al., 2010, Non-
motor dopamine withdrawal syndrome after surgery for
38. Castro-Caldas A, Delwaide P, Jost W, et al., 2006, The Parkinson’s disease: Predictors and underlying mesolimbic
Parkinson-control study: A 1‐year randomized, double‐ denervation. Brain, 133: 1111–1127.
blind trial comparing piribedil (150 mg/day) with
bromocriptine (25 mg/day) in early combination with https://doi.org/10.1093/brain/awq032
levodopa in Parkinson’s disease. Mov Disord, 21: 500–509. 50. Vale S, 2008, Current management of the cognitive
dysfunction in Parkinson’s disease: How far have we come?
https://doi.org/10.1002/mds.20750
Exp Biol Med (Maywood), 233: 941–951.
39. Rascol O, Dubois B, Caldas AC, et al., 2006, Early piribedil
monotherapy of Parkinson’s disease: A planned seven-month https://doi.org/10.3181/0707-MR-193
report of the REGAIN study. Mov Disord, 21: 2110–2115. 51. Richard IH, 2006, Apathy does not equal depression in
Parkinson disease: Why we should care. Neurology, 67: 10–11.
https://doi.org/10.1002/mds.21122
https://doi.org/10.1212/01.wnl.0000231141.03382.92
40. Rondot P, Ziegler M, 1992, Activity and acceptability
of piribedil in Parkinson’s disease: A multicentre study. 52. Aarsland D, Påhlhagen S, Ballard CG, et al., 2011, Depression
J Neurol, 239: S28–S34. in Parkinson disease--epidemiology, mechanisms and

Volume 2 Issue 1 (2023) 12 https://doi.org/10.36922/an.290